Jan 29 |
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
|
Jan 16 |
Top 4 Health Care Stocks That May Rocket Higher In Q1
|
Dec 26 |
Karuna downgraded, Arm target raised: Wall Street's top analyst calls
|
Dec 22 |
Dow Edges Lower; Nike Sales Miss Estimates
|
Dec 22 |
AlloVir halts Phase 3 studies over efficacy, stock plunges 65%
|
Dec 22 |
Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls
|
Dec 22 |
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
|
Nov 16 |
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
|
Nov 2 |
AlloVir GAAP EPS of -$0.39 beats by $0.01
|
Nov 2 |
AlloVir Inc (ALVR) Reports Q3 2023 Financial Results
|